Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
We will test the safety of a new class of anti-diabetes compounds (DPPIV-inhibitors) in
people living with HIV. Future trials will examine efficacy for treating diabetes and
reducing cardiovascular disease risk in people living with HIV.